N@N

CLDA, NVGN, PSTI, MSHL, CNSTQ, FRRVY, Removed From Naked Short Lists Today

^{Published on 2011-02-09 06:01:23 - WOPRAI}
 

February 9, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. CLINICAL DATA INC (NASDAQ:CLDA), NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN), PLURISTEM THERAPEUTICS INC (NASDAQ:PSTI), MARSHALL EDWARDS INC (NASDAQ:MSHL), Constar International Inc. (OTC:CNSTQ), FERROVIAL SA-UNSPONSORED ADR (OTC:FRRVY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

CLINICAL DATA INC (NASDAQ:CLDA) - Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers. The company was founded in 1969 and is headquartered in Newton, Massachusetts.There is a failure to deliver in shares of CLDA

NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN) - Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The companys consumer healthcare products comprise Promensil, a range of natural products specifically for womens health; Vinalac, a probiotic formula to help prevent childhood allergies, such as eczema in children at risk of an allergy; Aliten for weight control; and Trinovin, for the enhancement and maintenance of mens health. It focuses on oncology, cardiovascular, dermatological, and anti-inflammatory programs. The companys programs include Phenoxodiol, a phase III investigational drug for late stage, chemoresistant ovarian cancer and prostate, and cervical cancers; Triphendiol, a phase I signal transduction inhibitor for the treatment of cholangiocarcinoma or bile duct cancer, and stage IIB through stage IV malignant melanoma; NV-128, a pre-clinical stage cancer compound to promote cancer cell death in multidrug resistant ovarian cancer cells by targeting the AKT-mTOR pathway; and GLYC-101, a phase II product for the treatment of wounds following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers. Novogens programs also include NV-143, a derivative of triphendiol and a pan acting ant-cancer; NV-04, a program for cardiovascular disease; NV-27, an oral agent to prevent arterial restenosis following coronary artery angioplasty; and NV-07 for the protection of mice against UV-induced inflammatory changes in the skin and against UV-induced skin immune suppression. In addition, it develops NV-52 for the treatment of inflammatory bowel disease; and FAIMs, flavonoid anti-inflammatory molecules to avoid cardiovascular, gastrointestinal, and renal side effects associated with anti-inflammatory drugs. Novogen Limited offers its products in Australia, North America, and Europe. The company was founded in 1994 and is headquartered in North Ryde, Australia.There is a failure to deliver in shares of NVGN

PLURISTEM THERAPEUTICS INC (NASDAQ:PSTI) - Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the companys proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The companys principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.There is a failure to deliver in shares of PSTI

MARSHALL EDWARDS INC (NASDAQ:MSHL) - Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited.There is a failure to deliver in shares of MSHL

Constar International Inc. (OTC:CNSTQ) - Constar International Inc.There is a failure to deliver in shares of CNSTQ

FERROVIAL SA-UNSPONSORED ADR (OTC:FRRVY) - Ferrovial, S.A. operates as an infrastructure group in Spain and internationally. Its construction activities include designing and building of roads, railways, hydraulic works, maritime works, infrastructure, hydroelectric, and industrial works. The company also operates and manages eight airports. In addition, Ferrovial operates and manages 23 toll roads in Spain, Ireland, Portugal, Greece, Chile, Canada, and the United States. Further, the company provides facility management, infrastructure maintenance, airport handling, car park management and maintenance, and municipal and waste treatment services. Additionally, it owns the Heathrow airport in London; 407 express toll route in Toronto; and the Chicago Skyway and the Ausol toll roads in Spain. The company was formerly known as Cintra Concesiones De Infraestructuras De Transporte, S.A. and changed its name on December 7, 2009 to Ferrovial, S.A. as a result of absorption of Grupo Ferrovial, S.A. The company is based in Madrid, Spain.There is a failure to deliver in shares of FRRVY

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,750,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.

BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.

BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

Contact: Thomas Ronk / CEO www.BUYINS.net (800) 715-9999 tom@buyins.net